Blue Ridge Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Blue Ridge Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,338,300	Closed	-$170M	–	2
2017 Q4	$170M	Sell	1,338,300 -193,599	-13%	-$24.3M	5.66%	6
2017 Q3	$180M	Buy	1,531,899 +155,199	+11%	+$13.2M	3.23%	15
2017 Q2	$110M	Sell	1,376,700 -213,300	-13%	-$13.6M	1.92%	23
2017 Q1	$81.5M	Buy	1,590,000 +270,000	+20%	+$12.5M	1.06%	32
2016 Q4	$49.4M	Hold	1,320,000	–	–	0.62%	39
2016 Q3	$89.5M	Hold	1,320,000	–	–	1.06%	33
2016 Q2	$73.2M	Buy	1,320,000 +245,000	+23%	+$15.4M	0.95%	34
2016 Q1	$67.5M	Hold	1,075,000	–	–	0.82%	37
2015 Q4	$101M	Hold	1,075,000	–	–	1.13%	36
2015 Q3	$86.4M	Hold	1,075,000	–	–	0.99%	40
2015 Q2	$129M	Buy	1,075,000 +115,000	+12%	+$13.7M	1.45%	35
2015 Q1	$100M	Buy	960,000 +530,000	+123%	+$53.7M	1.14%	34
2014 Q4	$41.7M	Buy	+430,000	New	+$39.8M	0.51%	42

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Blue Ridge Capital's ALNY Position: Q1 2018 in Review

Blue Ridge Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2018, closing a stake of 1,338,300 shares — an estimated $170M sold.

Blue Ridge Capital first reported a position in ALNY in Q4 2014 and held it in 13 quarters. The position peaked at $180M in Q3 2017. 293 funds tracked by Wall St. Rank hold ALNY as of Q1 2018.

Blue Ridge Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Blue Ridge Capital sold 1,338,300 Alnylam Pharmaceuticals shares in Q1 2018, an estimated $170M.
Blue Ridge Capital first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 13 quarters.
Blue Ridge Capital's Alnylam Pharmaceuticals position peaked at $180M in Q3 2017.
293 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2018.

Based on Blue Ridge Capital's 13F filing for Q1 2018.